Skip to content

Our Approach

A Return to Normal

The body’s defense against pathogens requires proper immune function which depends on two major pillars: the innate immune system, operating as the first line of defense against pathogens, and the adaptive immune system, which generates cellular and humoral defenses against specific antigens. In a healthy immune system, these complex networks of cells, organs and tissues work together in harmony. However, when one or more components goes awry, the result can be a wide range of inflammatory and autoimmune diseases that can be debilitating and life-threatening, affecting millions of people worldwide.

Q32 Bio’s therapeutic approach targets endogenous regulators of both the innate and adaptive immune systems and is focused on restoring immune homeostasis. We are currently advancing two programs – a portfolio of therapeutic fusion proteins that deliver powerful negative regulators of complement activation directly to disease-affected tissues; and a fully human anti-IL-7Rα (CD127) antagonist antibody that modulates pathogenic T cell function by blocking IL-7 binding to the IL-7 receptor (CD127/CD132) and TSLP binding to the TSLP receptor complex (CD127/TSPLR).

diagram-mobile diagram-desktop

Restoring Innate Immunity:
Targeting Complement

Key to innate immunity is the complement system, a first line of defense for fighting pathogens and clearing apoptotic cells. However, when hyperactivated, it is a driver of a variety of autoimmune and inflammatory diseases in which the complement system attacks and damages healthy tissues. Many current therapeutic approaches target complement systemically, increasing the risk of serious infections. Q32 Bio is designing molecules that provide potent regulation of complement in diseased tissues without long-term systemic blockade – a key differentiator versus current complement therapeutics. Our lead complement fusion protein is called ADX-097, and is currently being evaluated in a Phase 1 clinical study.

Complement Program

Restoring Adaptive Immunity:
Targeting IL-7/TSLP

The IL-7 and TSLP receptors are implicated in driving pathogenic T-effector cells, suppressing T-regulatory cell function and inducing dendritic cell mediated TH2 responses. These receptors have been associated with the pathology of several inflammatory and autoimmune diseases. In partnership with Horizon Therapeutics, Q32 Bio is developing a fully human anti-IL-7Rα (CD127) antagonist antibody, ADX-914, that re-regulates immune function by blocking signaling mediated by both IL-7 and TSLP. A Phase 1 clinical study of ADX-914 has been completed and a Phase 2 program is expected to initiate in the second half of 2022.

IL-7/TSLP Program